StockData
Kalaris Therapeutics, Inc. logo

Kalaris Therapeutics, Inc. (KLRS) stock

KLRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.43−0.03 (-2.05%)

Close on Nov 17, 2026Market cap $34.04MP/E –Yield –

Kalaris Therapeutics profit margin

Profit margin (net margin) is net income as a percentage of revenue.

Kalaris Therapeutics's profit margin for the twelve months ending Dec 31, 2019 was -14447.9%. For fiscal 2019 it was -14447.9%.

Annual profit margin

PeriodPeriod endValueChange (pts)
FY2019Dec 31, 2019-14447.9%–

More Kalaris Therapeutics figures

See a number that looks wrong?